An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Trial Profile

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs Naquotinib (Primary) ; Erlotinib; Gefitinib
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SOLAR
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 22 Jun 2017 This trial has been suspended in Spain.
    • 03 Jun 2017 This trial has been suspended in Germany.
    • 10 May 2017 According to an Astellas Pharma media release, based on the recommendation by the Independent Data Monitoring Committee (IDMC), the company has announced the discontinuation of ASP8273 treatment arm in this trial. No new patients are being enrolled in ASP8273 trials and all patients currently receiving ASP8273 are encouraged to speak with their physician about their treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top